Evidence map›Paper›PMID 40951978›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Rates of clinical progression according to biological Alzheimer's disease stages.

Lydia Trudel, Joseph Therriault, Arthur C Macedo, Stijn Servaes, Seyyed Ali Hosseini, Gleb Bezgin, Nesrine Rahmouni, Tevy Chan, Jaime Fernandez-Arias, Étienne Aumont and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Using CA1 rather than the whole hippocampus to capture tau-PET Braak stage II.European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Article
  3. Visual versus quantitative tau-PET Braak staging in Alzheimer's disease using [European journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Predicting continuous amyloid PET levels with CSF and plasma brain-derived p-tau217.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Rates of clinical progression according to biological Alzheimer's disease stages.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Lydia TrudelTranslational Neuroimaging Laboratory Department of Neurology and Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.ORCID 0009-0002-5593-7717
Joseph TherriaultTranslational Neuroimaging Laboratory Department of Neurology and Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Arthur C MacedoTranslational Neuroimaging Laboratory Department of Neurology and Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Stijn ServaesTranslational Neuroimaging Laboratory Department of Neurology and Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Seyyed Ali HosseiniTranslational Neuroimaging Laboratory Department of Neurology and Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Gleb BezginTranslational Neuroimaging Laboratory Department of Neurology and Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Nesrine RahmouniTranslational Neuroimaging Laboratory Department of Neurology and Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Tevy ChanTranslational Neuroimaging Laboratory Department of Neurology and Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Jaime Fernandez-AriasTranslational Neuroimaging Laboratory Department of Neurology and Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Étienne AumontTranslational Neuroimaging Laboratory Department of Neurology and Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Yi-Ting WangTranslational Neuroimaging Laboratory Department of Neurology and Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Yansheng ZhengTranslational Neuroimaging Laboratory Department of Neurology and Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Brandon HallTranslational Neuroimaging Laboratory Department of Neurology and Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Robert HopewellPET Unit, McConnell Brain Imaging Centre, Montreal, Quebec, Canada.
Chris Hung-Hsin HsiaoPET Unit, McConnell Brain Imaging Centre, Montreal, Quebec, Canada.
Arthur W TogaMark and Mary Stevens Neuroimaging and Informatics Institute Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Meredith N BraskieMark and Mary Stevens Neuroimaging and Informatics Institute Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Karin L MeekerInstitute for Translational Research, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Jean-Paul SoucyTranslational Neuroimaging Laboratory Department of Neurology and Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Serge GauthierTranslational Neuroimaging Laboratory Department of Neurology and Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Paolo VitaliTranslational Neuroimaging Laboratory Department of Neurology and Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Sid E O'BryantInstitute for Translational Research, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Tharick A PascoalDepartment of Psychiatry School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Pedro Rosa-NetoTranslational Neuroimaging Laboratory Department of Neurology and Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.

Funding

Vascular Contributions to Dementia and Genetic Risk Factors for Alzheimer's DiseaseP01AG052350 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ARTHUR W TOGA · 2016 to 2026
$28.4M
USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI · 2020 to 2026
$27.8M
Understanding ethno-racial differences in AT(N)-defined heterogeneity profilesK01AG083115 · NIA · WASHINGTON UNIVERSITY · PI Karin Meeker · 2023 to 2026
$496k
Alzheimer's AssociationCIHRConsortium canadien en neurodégénérescence associée au vieillissementFondation Brain CanadaFonds de Recherche du Québec - SantéNIA NIH HHS K01 AG083115NIA NIH HHS L60 AG096756NIA NIH HHS P01 AG052350NIA NIH HHS P30 AG066530Weston Brain Institute
6 · The paper itself

Abstract

introductionPredicting the rate of cognitive decline and the likelihood of progression to dementia remains a critical unmet need in clinical settings.

methodsWe assessed progression to mild cognitive impairment (MCI) and all-cause dementia in 492 individuals from the TRIAD, ADNI, and HABS-HD cohorts followed for an average of 2.49 years. Amyloid-positive participants were staged according to the Alzheimer's Association biological staging framework (A+T

resultsCognitively unimpaired (CU) individuals in the A+T DISCUSSION: Our results highlight the prognostic value of biological AD staging. HIGHLIGHTS: Cognitively unimpaired (CU) individuals in all tau-PET (positron emission tomography)-positive biological Alzheimer's disease (AD) stages were at significantly higher risk of clinical progression compared to individuals without AD. In individuals with mild cognitive impairment (MCI), only the A+T

Indexed as

Alzheimer DiseaseCognitive DysfunctionDisease ProgressionAgedAged, 80 and overBrainCohort StudiesFemaleHumansLongitudinal StudiesMalePositron-Emission Tomographytau Proteinstau ProteinsAlzheimer's diseaseprognostic valuerisk of progressiontau‐PET imaging

Identifiers

PMID40951978
PMCPMC12434706

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.